Aramark (ARMK) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Aramark.

Q2 2020

→

Q1 2026

→

Analyst Coverage

Research analysts who have asked questions during Aramark earnings calls.

Jaafar Mestari

BNP Paribas

8 questions for ARMK

Also covers: DNUT, DUFRY, IHG

Jasper Bibb

Truist Securities

8 questions for ARMK

Also covers: ABM, AMN, APEI +15 more

Neil Tyler

Redburn Atlantic

8 questions for ARMK

Also covers: HRI, URI

Andrew J. Wittmann

Robert W. Baird & Co.

7 questions for ARMK

Also covers: ABM, ACM, APG +17 more

Andrew Steinerman

JPMorgan Chase & Co.

7 questions for ARMK

Also covers: BFAM, CTAS, DNB +16 more

Joshua Chan

UBS Group AG

6 questions for ARMK

Also covers: ABM, APG, BFAM +16 more

Leo Carrington

Citi

6 questions for ARMK

Also covers: CTAS, IHG

Toni Kaplan

Morgan Stanley

6 questions for ARMK

Also covers: ADT, BFAM, BV +18 more

Ian Zaffino

Oppenheimer & Co. Inc.

5 questions for ARMK

Also covers: ACA, ALSN, BOWL +21 more

Stephanie Moore

Jefferies

5 questions for ARMK

Also covers: APG, ARCB, BFAM +30 more

Shlomo Rosenbaum

Stifel, Nicolaus & Company, Incorporated

4 questions for ARMK

Also covers: CCC, CCCS, CLVT +19 more

Harold Antor

Jefferies Financial Group Inc.

3 questions for ARMK

Also covers: APG, BFAM, BV +9 more

Faiza Alwy

Deutsche Bank

2 questions for ARMK

Also covers: ABM, ADV, BFAM +18 more

Josh Shan

UBS

2 questions for ARMK

Karl Green

RBC Capital Markets

2 questions for ARMK

Also covers: BZLFY

Yehuda Silverman

Morgan Stanley

2 questions for ARMK

Also covers: ADT, BV, CTAS +4 more

Alexander EM Hess

JPMorgan Chase & Co.

1 question for ARMK

Also covers: BV, DNB, FICO +4 more

Elizabeth Dove

Goldman Sachs

1 question for ARMK

Also covers: CAR, CCL, CHH +12 more

Ian Defina

Oppenheimer

1 question for ARMK

Ian Difina

Oppenheimer

1 question for ARMK

Isaac Saulson

Oppenheimer & Co. Inc.

1 question for ARMK

Also covers: CCSI

Ryan Davis

Goldman Sachs

1 question for ARMK

Latest news

Recent press releases and 8-K filings for ARMK.

Aramark Reports Strong Q1 2026 Results and Reaffirms Full-Year Guidance

ARMK

Earnings

Guidance Update

Revenue Acceleration/Inflection

Aramark reported Q1 2026 organic revenue growth of 5% to $4.8 billion, which would have been approximately 8% excluding a calendar shift that negatively impacted revenue by an estimated $125 million. Adjusted EPS for the quarter was $0.51.
The company reaffirmed its full-year fiscal 2026 guidance, anticipating organic revenue growth of 7%-9%, Adjusted Operating Income (AOI) to increase 12%-17%, and adjusted EPS growth of 20%-25%.
Key growth drivers include extraordinary client retention and significant new client wins, such as Penn Medicine and RWJBarnabas Health in the U.S., alongside continued double-digit organic revenue growth in the International segment, which increased over 13% in Q1.
Aramark repurchased $30 million of shares and proactively repriced $2.4 billion of 2030 term loans, resulting in 25 basis points of interest expense savings.

Feb 10, 2026, 1:30 PM

Transcript

Aramark Reports Strong Q1 2026 Results and Reaffirms Full-Year Guidance

ARMK

Earnings

Guidance Update

Share Buyback

Aramark reported Q1 2026 organic revenue growth of 5% to $4.8 billion, which would have been approximately 8% without a calendar shift that unfavorably impacted revenue by about $125 million.
Adjusted Operating Income (AOI) grew 1% on a constant currency basis to $263 million, but would have increased approximately 11% without the $25 million impact from the calendar shift. Adjusted EPS was $0.51.
The company reaffirmed its full-year fiscal 2026 outlook, projecting organic revenue growth of 7%-9%, AOI increasing 12%-17%, and adjusted EPS growth of 20%-25%.
Operational highlights include extraordinary client retention and significant new client wins, particularly in healthcare, education, and corrections, with the company well on track to meet or exceed its 4%-5% net new target for fiscal 2026.
Aramark repurchased $30 million of shares and repriced $2.4 billion of 2030 term loans, resulting in 25 basis points of interest expense savings.

Feb 10, 2026, 1:30 PM

Transcript

Aramark Reports Strong Q1 2026 Results and Reaffirms Full-Year Guidance

ARMK

Earnings

Guidance Update

Share Buyback

Aramark reported Q1 2026 organic revenue growth of 5% to $4.8 billion, which would have been approximately 8% without a calendar shift that unfavorably impacted revenue by about $125 million.
Adjusted Operating Income (AOI) for Q1 2026 was $263 million, an increase of 1% on a constant currency basis, but would have grown approximately 11% without the estimated $25 million impact from the calendar shift.
The company reaffirmed its full-year fiscal 2026 guidance, expecting organic revenue growth of 7%-9%, AOI increasing 12%-17%, and adjusted EPS growth of 20%-25%.
Aramark secured significant new business wins, including Penn Medicine and RWJBarnabas Health, and repurchased $30 million of shares while optimizing its debt structure by repricing $2.4 billion of term loans.

Feb 10, 2026, 1:30 PM

Transcript

Aramark Announces Q1 Fiscal 2026 Results and Fiscal 2026 Outlook

ARMK

Earnings

Guidance Update

Dividends

Aramark reported Q1 Fiscal 2026 revenue growth of +6% and organic revenue growth of +5%, which would have been approximately +8% without the calendar shift.
Adjusted Operating Income (AOI) grew +1%, or approximately +11% without the calendar shift, and Adjusted EPS was unchanged, but would have grown approximately +13% without the calendar shift.
The company repurchased $30 million of stock in fiscal 2026 and increased its quarterly dividend by 14% to $0.12 per share in November 2025.
For fiscal 2026, Aramark anticipates organic revenue growth of +7% to +9%, Adjusted Operating Income growth of +12% to +17%, and Adjusted EPS growth of +20% to +25%. The company is also committed to reducing its leverage ratio to under 3.0x by the end of fiscal 2026.

Feb 10, 2026, 1:30 PM

Presentation

Aramark Reports Q1 Fiscal 2026 Results and Reaffirms Full-Year Outlook

ARMK

Earnings

Guidance Update

Share Buyback

Aramark reported Q1 fiscal 2026 revenue of $4.8 billion, an increase of 6% year-over-year, with organic revenue growing 5%.
Adjusted EPS remained unchanged at $0.51 for Q1 fiscal 2026, while GAAP EPS decreased 8% to $0.36. The company noted that a calendar shift reduced growth across key metrics, with Adjusted EPS growth estimated at +13% without this impact.
During the quarter, Aramark repurchased $30 million of stock and favorably repriced $2.4 billion of 2030 Term Loans by 25 basis points.
The company reaffirmed its fiscal 2026 outlook, projecting revenue between $19.55 billion and $19.95 billion (organic growth of +7% to +9%), Adjusted Operating Income between $1.1 billion and $1.15 billion (organic growth of +12% to +17%), and Adjusted EPS between $2.18 and $2.28 (growth of +20% to +25%).

Feb 10, 2026, 11:34 AM

8-K

Aramark Reports First Quarter Fiscal 2026 Results

ARMK

Earnings

Guidance Update

Share Buyback

Aramark reported first quarter fiscal 2026 revenue of $4,831,549 thousand, a 6% increase year-over-year, with organic revenue growth of 5%. Adjusted EPS remained unchanged at $0.51, though the company noted a calendar shift negatively impacted Q1 growth but is expected to provide a favorable impact in Q2.
For fiscal year 2026, Aramark anticipates revenue between $19,550 million and $19,950 million and Adjusted EPS between $2.18 and $2.28. The company also expects its Leverage Ratio to be under 3x by the end of fiscal 2026.
The company continued its capital allocation priorities by repurchasing $30 million of stock and favorably repricing $2.4 billion of 2030 Term Loans. A quarterly dividend of $0.12 per share was also approved.

Feb 10, 2026, 11:31 AM

Press Release

Aramark Reports Q1 Results, Reaffirms Guidance

ARMK

Earnings

Guidance Update

Revenue Acceleration/Inflection

Aramark reported Q1 revenue of approximately $4.83 billion and adjusted EPS of $0.51, slightly topping estimates.
The company reaffirmed its fiscal 2026 revenue guidance of $19.55 billion–$19.95 billion.
Management emphasized record-high client retention, strong net new business, and major multi-year contract wins, including Penn Medicine and RWJBarnabas.
FSS International achieved over 13% organic growth, marking its nineteenth consecutive quarter of double-digit international growth.
A calendar shift reduced reported organic revenue growth by about 3% (approximately $125 million) and adjusted operating income by about $25 million.

Feb 9, 2026, 3:58 PM

Morningstar

Aramark expands partnership and makes equity investment in Venu Holding Corporation

ARMK

New Projects/Investments

Aramark Sports + Entertainment has expanded its multi-venue partnership with Venu Holding Corporation (VENU).
Under the expanded agreement, Aramark will now support five of VENU’s premium multi-seasonal and outdoor venues.
Aramark will deliver elevated food and beverage, premium club dining, facilities management, and retail services for these venues.
The partnership also includes an additional equity investment by Aramark in VENU.

Jan 15, 2026, 1:55 PM

Press Release

U.S. Contract Catering Market Projected to Exceed $110 Billion by 2030

ARMK

New Projects/Investments

Revenue Acceleration/Inflection

The U.S. Contract Catering Market was valued at $73.31 billion in 2024 and is projected to grow to $110.17 billion by 2030, demonstrating a Compound Annual Growth Rate (CAGR) of 7.02%.
The market is consolidated, with Compass Group PLC, Aramark, and Sodexo leading and collectively contributing over 50% of the market share.
Major trends driving market growth include Digitalization & Tech Integration (e.g., AI-driven menu planning, contactless payment) and Ethical Sourcing & Sustainability (e.g., zero-waste kitchens, local sourcing).
The market faces a significant challenge from intense competition coupled with pricing pressure, making it difficult for smaller players to compete with the scale and purchasing power of larger companies.

Jan 6, 2026, 10:51 AM

Press Release

Aramark Services Refinances Debt with New Term Loans

ARMK

Debt Issuance

Aramark Services, Inc., an indirect wholly owned subsidiary of Aramark, entered into Amendment No. 19 to its Credit Agreement on December 11, 2025.
This amendment provides for the repricing of all previously outstanding U.S. Term B-8 Loans by refinancing them with new U.S. Term B-10 Loans in an aggregate principal amount of $2,384,140,862.90.
The new U.S. Term B-10 Loans are due in June 2030 and bear interest at a rate equal to Term SOFR plus 1.75% or a base rate plus 0.75%.
Principal repayments for the U.S. Term B-10 Loans are required in quarterly installments of $6,290,609.14, commencing December 31, 2028, and continuing through March 31, 2030.